Is lenvatinib/lenvatinib a targeted drug or an immunotherapy drug?

Lenvatinib/Lenvatinib is a targeted drug, not an immunotherapy drug. It is a multi-target tyrosine kinase inhibitor that mainly works by interfering with the growth signaling pathways of cancer cells and inhibiting angiogenesis. The mechanism of action of lenvatinib focuses on the inhibition of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), insulin-like growth factor receptor (IGF-1R) and other related targets. This multi-target mechanism of action allows lenvatinib to effectively inhibit the proliferation and migration of tumor cells while reducing tumor blood supply, thereby achieving the purpose of controlling tumor growth.

Unlike traditional chemotherapy drugs, targeted drugs such as lenvatinib selectively attack cancer cells, often with fewer side effects. This is because targeted drugs primarily act on specific molecular pathways rather than broadly affecting all cells that kill quickly. Through this precise treatment, lenvatinib can provide effective treatment options for patients with many types of cancer, including thyroid, kidney, and liver cancer.

Immunotherapy drugs mainly work by activating the patient's own immune system to identify and attack cancer cells. Common immunotherapy includes immune checkpoint inhibitors, cell therapy, etc. These treatments are designed to enhance or restore the body's immune response to fight tumors. In contrast, targeted drugs mainly focus on specific biomarkers and molecular mechanisms to achieve therapeutic effects by directly intervening in the biological processes of tumors.

Overall, lenvatinib, as part of targeted therapy, represents an important direction in modern cancer treatment. Its success in clinical application has further promoted the development and use of targeted drugs and brought new hope to many cancer patients.

Reference materials:https://www.lenvima.com/